<?xml version="1.0" encoding="UTF-8"?>
<p id="p0115">Over the past decades extensive efforts have been made to develop new drug alternatives in endemic countries. In general, a wide range of antileishmanial plant extracts have been evaluated as evidenced from Iran (
 <xref rid="bb0020" ref-type="bibr">Bahmani et al., 2015</xref>), French Guiana (
 <xref rid="bb0105" ref-type="bibr">Rocha et al., 2005</xref>), India (
 <xref rid="bb0115" ref-type="bibr">Samuelsson and Bohlin, 2017</xref>), Israel (
 <xref rid="bb0065" ref-type="bibr">El-On, 2009</xref>) and Greece (
 <xref rid="bb0075" ref-type="bibr">Fokialakis et al., 2007</xref>). There seem new approaches toward the natural products, in absence of effective agents would be a logical strategy (
 <xref rid="bb0080" ref-type="bibr">Harvey et al., 2015</xref>). Unfortunately; although, despite the use of natural products in endemic countries only a limited effort has been made to isolate and analyze their chemical antileishmanial compositions to conduct clinical trials.
</p>
